V
Vincent Dive
Researcher at French Alternative Energies and Atomic Energy Commission
Publications - 105
Citations - 4673
Vincent Dive is an academic researcher from French Alternative Energies and Atomic Energy Commission. The author has contributed to research in topics: Matrix metalloproteinase & Angiotensin-converting enzyme. The author has an hindex of 38, co-authored 103 publications receiving 4294 citations. Previous affiliations of Vincent Dive include Alternatives & Commissariat à l'énergie atomique et aux énergies alternatives.
Papers
More filters
Journal ArticleDOI
An adult tissue-specific stem cell in its niche: a gene profiling analysis of in vivo quiescent and activated muscle satellite cells.
Giorgia Pallafacchina,Stéphanie François,Béatrice Regnault,Bertrand Czarny,Vincent Dive,Ana Cumano,Didier Montarras,Margaret Buckingham +7 more
TL;DR: It is demonstrated that metalloproteinase function is required for efficient regeneration in vivo, and revealed how the satellite cell protects itself from damage and maintains quiescence, while being primed for activation on receipt of the appropriate signal.
Journal ArticleDOI
A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity
David Marchant,Caroline L. Bellac,Theo J. Moraes,Samuel J. Wadsworth,Antoine Dufour,Georgina S. Butler,Leanne M. Bilawchuk,Reid G. Hendry,A. Gordon Robertson,Caroline Cheung,Julie Ng,Lisa S. Ang,Zongshu Luo,Karl Heilbron,Michael J Norris,Wenming Duan,Taylor Bucyk,Andrei Karpov,Laurent Devel,Dimitris Georgiadis,Richard G. Hegele,Honglin Luo,David J. Granville,Vincent Dive,Bruce M. McManus,Christopher M. Overall +25 more
TL;DR: It is shown that after macrophage secretion, MMP-12 is transported into virus-infected cells, and it is suggested that inhibiting extracellular M MP-12 could be a new avenue for the development of antiviral treatments.
Journal ArticleDOI
RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites
Vincent Dive,Joël Cotton,Athanasios Yiotakis,Annie Michaud,Stamatia Vassiliou,Jiri Jiracek,Gilles Vazeux,Marie-Thérèse Chauvet,Philippe Cuniasse,Pierre Corvol +9 more
TL;DR: RXP 407, a highly potent and selective inhibitor of the N-terminal active site of wild ACE, may lead to a new generation of ACE inhibitors able to block in vivo only a subset of the different functions regulated by ACE.
Journal ArticleDOI
Roles of the Two Active Sites of Somatic Angiotensin-Converting Enzyme in the Cleavage of Angiotensin I and Bradykinin Insights From Selective Inhibitors
Dimitris Georgiadis,Fabrice Beau,Bertrand Czarny,Joël Cotton,Athanasios Yiotakis,Vincent Dive +5 more
TL;DR: In vivo the conversion of Ang I seems to involve the two active sites of ACE, free of inhibitor, and it might be suggested that the gene duplication of ACE in vertebrates may represent a means for regulating the cleavage of angiotensin I differently from that of BK.
Journal ArticleDOI
Development of selective inhibitors and substrate of matrix metalloproteinase-12.
Laurent Devel,Vassilis Rogakos,Arnaud David,A. Makaritis,Fabrice Beau,Philippe Cuniasse,Athanasios Yiotakis,Vincent Dive +7 more
TL;DR: Two phosphinic peptides identified may have important therapeutic applications to diseases in which MMP-12 has been suggested to play a key role, such as in emphysema, atherosclerosis, and aortic abdominal aneurysm.